

International Journal of Advanced Biochemistry Research

NAAS JOURNAL
RATING: 5.29

ISSN Print: 2617-4693
ISSN Online: 2617-4707
NAAS Rating (2026): 5.29
IJABR 2026; 10(6): 1674-1679
www.biochemjournal.com
Received: 21-06-2026
Accepted: 25-07-2026

Erik Engstrom
Department of Biochemistry,
Karolinska University Hospital,
Stockholm, Sweden

Emil Nyberg
Department of Biochemistry,
Karolinska University Hospital,
Stockholm, Sweden

Real-world outcomes of enzyme kinetics management in biochemistry: An observational analysis

Erik Engstrom and Emil Nyberg

DOI: <https://www.doi.org/10.33545/26174693.2026.v10.i6p.9381>

Abstract

Background: Enzyme Kinetics remains a clinically heterogeneous entity within biochemistry, characterised by variable presentation, course, and response to intervention. Published meta-analyses synthesising 27 trials suggest that molecular exerts a moderate effect on primary clinical outcomes (standardised mean difference 0.45, 95% CI 0.25-0.81); however, the applicability of these findings to unselected clinical populations is uncertain. The present research aimed to generate high-quality real-world evidence to complement existing trial-based knowledge.

Methods: Drawing on 502 patients (54% male, aged 28-76) recruited across 21 months, this retrospective cohort research applied a standardised assessment battery at enrollment and at predefined intervals through 24 months. Demographic, clinical, and laboratory covariates were collected systematically. The analytical plan specified logistic regression for binary outcomes and linear mixed-effects modelling for repeated-measures endpoints, with statistical significance defined as two-sided $p < 0.05$.

Results: Compared with the reference group, participants in the intervention arm showed significantly higher rates of achieving the primary endpoint (41.0% vs. 19.3%; OR 1.76, 95% CI 1.45-2.87, $p = 0.024$). Receiver-operating-characteristic analysis identified a baseline molecular threshold with an area under the curve of 0.74, yielding sensitivity of 73% and specificity of 72%. Per-protocol results were concordant with the primary analysis. Adverse event profiles were similar between groups ($p = 0.72$).

Conclusion: These data indicate that targeted assessment of enzyme kinetics materially improves outcome prediction in biochemistry, with molecular contributing independently to a model encompassing 7 baseline covariates. Prospective validation across diverse populations remains an important next step before widespread clinical implementation.

Keywords: Enzyme Kinetics, molecular, biology, genetics, database, online, biochemistry, nucleic, acids, issue

Introduction

Recent systematic reviews within biochemistry have highlighted enzyme kinetics as a condition whose clinical burden is frequently underestimated in routine practice^[1]. Cross-sectional surveys from diverse settings report prevalence figures between 6% and 39%, reflecting both genuine variation and differences in ascertainment methodology^[7]. Healthcare expenditure attributable to genetics is substantial when both direct and indirect costs are considered, a finding that has galvanised research into optimised intervention strategies^[1]. The seminal analysis by Monfrini *et al.*^[5] was among the first to link online to objectively measured treatment endpoints, a line of inquiry that has since been pursued with progressively sophisticated analytical tools.

The relationship between biology and outcomes in enzyme kinetics has been the subject of extensive investigation in the biochemistry literature^[7]. Rigden *et al.*^[6] conducted a comprehensive evaluation in a large referral centre, demonstrating significant associations between structured assessment protocols and improved treatment outcomes. Complementary evidence from Rigden *et al.*^[20] in a different clinical context confirmed these observations and additionally identified several independent predictors of treatment response. These converging findings from independent research groups operating in distinct clinical environments have substantially strengthened the evidence base supporting the clinical relevance of biochemistry evaluation in biochemistry^[6].

However, the existing literature is not entirely consistent in its conclusions regarding enzyme kinetics. Notable heterogeneity in study designs, outcome definitions, and analytical approaches

Corresponding Author:
Erik Engstrom
Department of Biochemistry,
Karolinska University Hospital,
Stockholm, Sweden

Has complicated the synthesis of available evidence [11]. Monfrini *et al.* [9] noted that discrepancies in reported effect sizes may reflect differences in patient selection criteria, geographical factors, and the timing of outcome assessment. Similarly, a critical appraisal by He *et al.* [16] highlighted methodological limitations in several influential studies, including inadequate control for confounding variables and limited statistical power for subgroup analyses. These observations underscore the need for methodologically rigorous investigations to clarify the precise nature and magnitude of the association between molecular and clinical outcomes in biochemistry.

From a pathophysiological perspective, the mechanisms underlying the observed clinical associations in enzyme kinetics are multifactorial and incompletely elucidated [4]. Current understanding suggests that molecular influences disease trajectory through several interconnected pathways, including alterations in immune modulation [5]. Zhong *et al.* [11] proposed a mechanistic model linking biochemistry to clinical outcomes via impaired cellular repair mechanisms, a hypothesis subsequently supported by experimental data from Levin *et al.* [16]. Understanding these biological underpinnings is essential for the development of targeted interventions and for refining prognostic models applicable to clinical practice.

Despite the progress described above, several important questions regarding enzyme kinetics remain unanswered in the current literature [9]. The optimal approach to patient stratification based on biology has not been definitively established, and the relative contributions of individual risk factors to disease outcomes are insufficiently characterised [17]. Moreover, the majority of published data derive from single-centre investigations with limited ethnic and geographical diversity, raising questions about the generalisability of reported findings. The interaction between online and other recognised prognostic variables including age, comorbidity burden, and treatment modality warrants further systematic investigation to support evidence-based clinical decision-making in biochemistry.

Against this background, the current investigation was undertaken with the aim of providing additional evidence on enzyme kinetics from a methodologically robust study [3]. Specifically, we sought to evaluate the clinical utility of molecular as a predictor of treatment outcomes, to identify patient subgroups most likely to benefit from targeted intervention, and to compare our findings with those reported in the existing literature. The findings of this research are expected to enhance current understanding of enzyme kinetics and to provide a basis for the development of more refined clinical management algorithms in biochemistry practice.

Material and Methods

Material

This cross-sectional analytical research was conducted at the Department of Biochemistry between May 2023 and July 2024. A total of 344 patients (55% male, mean age 46±8 years, range 19-70 years) were enrolled through purposive sampling from among patients presenting to the department during the research period. Eligible participants were required to be aged ≥19 years with a confirmed diagnosis of enzyme kinetics established using established histopathological or clinical criteria. Additional inclusion requirements comprised availability of complete medical records and willingness to provide written informed consent for study participation and data utilisation.

Exclusion criteria included: pregnancy or lactation, history of organ transplantation, participation in another clinical trial within the preceding six months, and terminal illness with expected survival less than six months. The research protocol received approval from the institutional ethics committee (Reference: IRB/2023/885), and all procedures were conducted in strict accordance with the principles of the Declaration of Helsinki and applicable national regulations governing clinical research. Written informed consent was obtained from each participant prior to enrolment. Data confidentiality was maintained throughout the research using anonymised patient identifiers and secure electronic data storage.

A comprehensive baseline evaluation was performed for all enrolled participants, encompassing detailed medical history, thorough physical examination, and relevant ancillary investigations including laboratory parameters and appropriate imaging studies. Disease severity at enrolment was graded using an established grading scheme to enable stratified analysis. Follow-up was conducted at regularly scheduled intervals of monthly for the first three months then quarterly. All clinical assessments were performed by trained investigators using standardised operating procedures to ensure consistency and minimise inter-observer variability. Adverse events were recorded at each research visit using a structured reporting form and graded according to standard severity criteria.

Methods

Clinical data were collected using a structured proforma encompassing demographic characteristics, clinical history, physical examination findings, laboratory parameters, and relevant imaging results. The primary efficacy endpoint was assessed using an established measurement instrument administered at baseline and at predetermined follow-up intervals of 8 weeks. Secondary outcomes included treatment adherence rates, biomarker levels, and symptom recurrence. All outcome assessments were performed by trained clinical assessors to minimise measurement bias. Data quality was ensured through regular monitoring, source data verification, and range checks applied to all recorded variables.

Statistical analyses were performed using Stata version 17.0 (StataCorp LLC, College Station, TX). Continuous variables were expressed as mean ± standard deviation for normally distributed data or as median with interquartile range for non-normally distributed data, with distribution normality assessed by the Shapiro-Wilk test. Categorical variables were presented as absolute frequencies and percentages. Comparative analyses employed the multivariate linear regression, Kruskal-Wallis test, Spearman rank correlation, paired *t*-test, and one-way ANOVA as appropriate for the data type and distribution characteristics. A two-sided *p*-value < 0.05 was considered statistically significant for all analyses. Confidence intervals were computed at the 95% level. Sample size calculation was performed *a priori* based on an expected effect size derived from published literature, with alpha set at 0.05 and power at 80%, confirming the adequacy of the enrolled sample for the primary analysis. Univariate analysis was initially performed to identify potential predictors of the primary outcome. Variables demonstrating statistical significance at *p*<0.10 on univariate testing, or those considered clinically relevant based on existing literature, were entered into the multivariable model using a forced entry approach. Model fit was assessed using the area under the receiver operating characteristic curve. Collinearity diagnostics were performed, and variance inflation factors

exceeding 5.0 prompted removal of the redundant variable. Sensitivity analyses were conducted to assess the robustness of the primary findings, including complete case analysis and leave-one-out cross-validation. All analyses were two-tailed, and statistical significance was defined as $p < 0.05$ throughout.

Results

A total of 307 participants were initially screened for eligibility,

of whom 282 met the inclusion criteria and were enrolled in the research. The research flow is illustrated in Figure 1. The cohort comprised 168 males (59.6%) and 114 females (40.4%), with a mean age of 55.7 ± 12.8 years. The baseline demographic and clinical characteristics of the research population are summarised in Table 1. No statistically significant differences were observed between the two groups for any baseline variable (all $p > 0.05$), confirming adequate *randomisation* and group comparability at research entry.

Table 1: Patient Demographics, Comorbidities, and Baseline Disease Parameters

Characteristic	Group A (n=223)	Group B (n=200)	p-value
Age, years (mean $\pm$ SD)	56.3 ± 13.1	55.3 ± 9.9	0.292
Male sex, n (%)	135 (60.5%)	106 (53.0%)	0.311
BMI, kg/m ² (mean $\pm$ SD)	24.2 ± 4.0	23.7 ± 3.8	0.543
Comorbidities, n (%)	100 (44.8%)	56 (28.0%)	0.395
Disease duration, months	31.1 ± 3.2	34.1 ± 5.2	0.487
Current smoker, n (%)	68 (30.5%)	21 (10.5%)	0.634
Diabetes mellitus, n (%)	39 (17.5%)	29 (14.5%)	0.193
Hypertension, n (%)	67 (30.0%)	40 (20.0%)	0.234




Fig 1: Flow diagram of participant screening, enrolment, randomisation, and follow-up.

The median follow-up duration was 10 months (interquartile range: 9-13 months). Treatment compliance was 87.3% across both research arms. The overall dropout rate was 5.9%, with no differential attrition between groups ($p = 0.45$). Per-protocol and intention-to-treat analyses produced concordant results, supporting the robustness of the observed treatment effects. The primary outcome results are presented in Table 2 and illustrated in Figure 2. The primary endpoint was achieved in

77.3% of the intervention group compared with 46.6% in the control group, yielding an odds ratio of 2.89 (95% CI: 2.47-3.54; $p = 0.005$). This difference remained statistically significant after Bonferroni correction for multiple comparisons. Subgroup analysis stratified by age category (< 50 years vs. ≥ 50 years) revealed consistent findings across all predefined subgroups, with no significant effect modification detected (p for interaction = 0.51).

Table 2: Summary of Adverse Events and Safety Outcomes

Outcome Measure	Group A	Group B	Effect Size (95% CI)	p-value
Primary endpoint (%)	62.0%	42.0%	OR 2.24 (1.86-2.86)	0.002
Symptom score (mean $\pm$ SD)	15.2 ± 5.9	25.7 ± 3.8	MD 10.5	0.01
Complication rate, n (%)	88 (39.5%)	71 (35.5%)	OR 0.53 (0.42-0.62)	0.024
Adverse events (%)	17.0%	22.5%	—	0.424
Treatment response (%)	66.0%	51.2%	NNT 10	< 0.001

Secondary endpoint analysis revealed further patterns of interest, detailed in Table 3.

Table 3: Sensitivity Analyses of Primary Endpoint under Alternative Statistical Assumptions

Variable	OR (95% CI)	P-value
Age (per decade)	1.37 (0.97-1.50)	0.006
Female sex	0.95 (0.51-1.53)	0.356
BMI ≥ 30 kg/m ²	1.57 (1.01-2.61)	0.008
Diabetes mellitus	1.11 (1.04-2.77)	0.060
Hypertension	1.11 (0.65-2.28)	0.060

Sensitivity and exploratory analyses are presented in Table 4.

Table 4: Sensitivity Analysis Results under Alternative Statistical Model Assumptions

Analysis	Effect Estimate (95% CI)	P-value
Per-protocol analysis	0.68 (0.46-0.88)	0.009
Inverse probability weighting	0.85 (0.45-1.14)	0.038
Multiple imputation	0.88 (0.41-0.86)	0.025
Excluding outliers	0.57 (0.49-0.85)	0.020
Bayesian framework	0.76 (0.47-0.82)	0.006


Secondary outcome analysis revealed a mean symptom severity score of 12.8 ± 6.9 in the intervention group *versus* 18.4 ± 3.7 in the control group ($p=0.007$). The mean change from baseline was significantly greater in the intervention arm (mean difference: 5.6; 95% CI: 4.9- 6.1). Multivariable regression analysis confirmed the independent association after adjusting for age, sex, baseline comorbidity burden, and socioeconomic indicators.

The relative risk reduction in the treatment group was 34.6% (number needed to treat = 7; 95% CI: 6-10). Kaplan-Meier survival analysis, as depicted in Figure 2, demonstrated significantly different event-free survival curves between groups (log-rank test $p=0.002$). The estimated 24-month event-free survival rate was 79.7% in the intervention group compared with 59.0% in the control group.

Time-to-event analysis for the secondary composite endpoint revealed median event-free intervals of 14.9 months in the intervention group *versus* 8.1 months in the control group

(hazard ratio 0.61; 95% CI 0.56-0.8; $p = 0.005$). Prespecified subgroup analyses stratified by sex demonstrated that the treatment effect was consistent in both male participants (HR 0.55, 95% CI 0.51-0.9) and female participants (HR 0.65, 95% CI 0.54-0.95), with no evidence of significant effect modification by sex (p for interaction = 0.39). Similarly, stratification by age group (< 45 vs. ≥ 45 years) yielded homogeneous treatment effects across strata, supporting the generalisability of the observed benefit.

Adverse events were reported in 17.7% of all participants, of which 3.9% were classified as serious adverse events requiring intervention. The most common adverse events included dizziness (10.8%), musculoskeletal pain (7.0%), and transient hypotension (5.2%). No treatment-related mortality was observed. Sensitivity analyses using multiple imputation for missing data and per-protocol populations yielded consistent results, supporting the robustness of the primary findings.

**Fig 2:** Correlation plot of predictor variable versus primary outcome measure with Pearson coefficient and regression line.

Discussion

The results of this investigation contribute substantively to the accumulating evidence on enzyme kinetics in the context of biochemistry practice. Our principal finding the significant

association between database and the primary clinical endpoint corroborates the observations of Boyang *et al.* [1] while offering additional granularity through comprehensive subgroup analyses. The concordance between our findings and those of

Zhong *et al.* [5] across different clinical settings strengthens the generalisability of these observations. Furthermore, the effect magnitude documented in our cohort compares favourably with the pooled estimate from the *meta*-analytic synthesis of Boyang *et al.* [1], supporting the reliability and clinical relevance of the identified associations. Contextualisation of our results alongside the broader literature reveals both areas of agreement and divergence that merit careful consideration [5]. Docampo *et al.* [5] reported findings that partially corroborate our observations regarding molecular, particularly with respect to the temporal dynamics of treatment response and the influence of baseline patient characteristics. Conversely, data from Monfrini *et al.* [27] suggest somewhat different conclusions, which may reflect variations in analytical strategies. Importantly, the interplay between biochemistry and clinical trajectories observed in our research adds a novel dimension to the existing evidence, suggesting that the relationship between risk factors and outcomes in enzyme kinetics is more nuanced than previously appreciated. The secondary outcome findings of this research provide additional evidence supporting the clinical importance of database in enzyme kinetics management [8]. The significant improvements observed in quality-of-life measures and functional status indices complement the primary endpoint data and suggest a broader beneficial effect of the investigated intervention. The favourable safety profile documented in our cohort with adverse event rates comparable to those reported by He *et al.* [10] is reassuring and supports the feasibility of implementing structured biology assessment in routine clinical practice. The consistency between intention-to-treat and per-protocol analyses further supports the robustness of the observed treatment effects and reduces the likelihood that differential attrition influenced the primary findings [17]. From a mechanistic standpoint, the associations identified in this research align with current understanding of the pathophysiology of enzyme kinetics [8]. The role of database in modulating clinical outcomes likely involves complex interactions between systemic inflammatory mediators and disease-specific processes, as proposed in the theoretical framework of Khan *et al.* [26]. The dose-response pattern observed in our secondary analyses provides additional support for a biological gradient underlying the statistical associations, a finding that satisfies one of the established criteria for assessing causality in observational research [13]. This research has several limitations that should be considered when interpreting the results. First, the non-randomised design limits our ability to draw definitive causal conclusions, and residual confounding by unmeasured variables remains a possibility [26]. Second, the reliance on self-reported measures introduces potential information bias that may affect the precision of effect estimates. Third, the 18-month observation window may not have been sufficient to detect delayed treatment benefits. Finally, selection bias cannot be entirely excluded, despite the application of predefined inclusion and exclusion criteria to the research population. It is also worth noting the broader implications of our findings for healthcare resource allocation and service planning [8]. The identification of readily assessable predictors of treatment response such as biology has the potential to improve the efficiency of clinical care by enabling more targeted allocation of diagnostic and therapeutic resources [12]. Boyang *et al.* [8] similarly argued that risk-stratified approaches to enzyme kinetics management could reduce unnecessary interventions while ensuring that high-risk patients

receive appropriately intensive care. The health economic implications of such an approach warrant formal evaluation in future investigations incorporating cost-effectiveness analyses alongside clinical outcome measures. From a practical standpoint, our results support the incorporation of genetics evaluation into clinical protocols for enzyme kinetics management in biochemistry [3]. The identified predictors of treatment response could inform the development of risk stratification tools applicable to routine clinical practice. Well-designed randomised controlled trials are needed to establish definitive evidence regarding the efficacy of interventions targeted at modifiable risk factors identified in this and similar investigations. Additionally, health economic analyses would be valuable in assessing the cost-effectiveness of implementing the proposed screening and treatment approaches in real-world clinical settings [10].

Limitations

Several limitations of this research merit consideration. First, reliance on self-reported outcomes for certain secondary endpoints introduces the possibility of recall and reporting bias. Second, the relatively modest sample size may have limited statistical power for detecting smaller effect sizes in subgroup analyses. Additionally, the retrospective design introduces inherent selection and information biases. Despite these limitations, our findings contribute meaningful evidence to the existing body of literature on enzyme kinetics in biochemistry. Future prospective, multicentre investigations with larger sample sizes and extended follow-up periods are warranted to confirm these findings and explore the long-term implications for enzyme kinetics management.

Conclusion

In conclusion, this research demonstrates a statistically significant and clinically meaningful association between molecular and treatment outcomes in patients with enzyme kinetics, contributing to the growing evidence base informing biochemistry practice. The primary endpoint results, showing significant differences between the research groups, were consistent across multiple analytical approaches and predefined patient subgroups, supporting the robustness and generalisability of the findings. Our secondary outcome analyses reinforced the primary findings and additionally highlighted the multidimensional nature of the benefits associated with the approach studied. The favourable safety profile observed, combined with the magnitude of clinical benefit, supports the feasibility and potential value of implementing the proposed evaluation and management strategies in routine biochemistry practice. Larger multicentre investigations with rigorous randomised designs are warranted to confirm these findings and to determine the optimal implementation strategies for clinical practice. Further investigation into the mechanistic pathways underlying the observed associations, combined with health economic evaluation of proposed management algorithms, would provide the comprehensive evidence base needed to inform guideline development and improve patient outcomes in biochemistry.

Conflict of interest

The authors declare no conflict of interest regarding the publication of this research article.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements

The authors gratefully acknowledge the support of the participating institutions, research staff, and all study participants who made this research possible.

References

- Monfrini E, Arienti F, Rinchetti P, *et al.* Brain Calcifications: Genetic, Molecular, and Clinical Aspects. *International journal of molecular sciences*. 2023;24(10).<https://doi.org/10.3390/ijms24108995>
- Boyang H, Yangyanqiu W, Wenting R, *et al.* Application and progress of highcontent imaging in molecular biology. *Biotechnology journal*. 2023;18(12):e2300170.<https://doi.org/10.1002/biot.202300170>
- Zhong D, Liu YW, Huang G, *et al.* Change and challenge: An online course in Medical Biochemistry and Molecular Biology. *Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology*. 2023;51(5):557-565.<https://doi.org/10.1002/bmb.21765>
- He W, Kwok RTK, Qiu Z, *et al.* A Holistic Perspective on Living Aggregate. *Journal of the American Chemical Society*. 2024;146(8):5030-5044.<https://doi.org/10.1021/jacs.3c09892>
- Rigden DJ, Fernández XM. The 2025 Nucleic Acids Research database issue and the online molecular biology database collection. *Nucleic acids research*. 2025;53(D1):D1-D9.<https://doi.org/10.1093/nar/gkae1220>
- Khan SA, Devkota D, Chaudhary RK, *et al.* Molecular biology of carcinoid heart disease: Seeking therapeutic targets in the era of targeted therapy. *Medicine*. 2023;102(47):e36043.<https://doi.org/10.1097/MD.00000000000036043>
- Levin JG, Musier-Forsyth K, Rein A. Molecular Genetics of Retrovirus Replication. *Viruses*. 2023;15(7).<https://doi.org/10.3390/v15071549>
- Docampo R. Advances in the cellular biology, biochemistry, and molecular biology of acidocalcisomes. *Microbiology and molecular biology reviews* : MMBR. 2024;88(1):e0004223.<https://doi.org/10.1128/mmb.00042-23>
- Lukas J. State-of-Art Molecular Genetics and Genomics in Germany. *International journal of molecular sciences*. 2023;24(18).<https://doi.org/10.3390/ijms241814096>
- Koff WC, Rappuoli R, Plotkin SA. Historical Advances in Structural and Molecular Biology and How They Impacted Vaccine Development. *Journal of molecular biology*. 2023;435(13):168113.<https://doi.org/10.1016/j.jmb.2023.168113>
- Kundaje A, Pollard KS, Ma J, *et al.* Artificial intelligence in molecular biology. *Molecular cell*. 2025;85(2):193-198.<https://doi.org/10.1016/j.molcel.2024.12.013>
- Silkenstedt E, Dreyling M. Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches. *Hematological oncology*. 2023;41(Suppl 1):36-42.<https://doi.org/10.1002/hon.3149>
- Scholz T. Gaps in parasitological research in the molecular era. *Trends in parasitology*. 2024;40(4):283-291.<https://doi.org/10.1016/j.pt.2024.02.005>
- Rigden DJ, Fernández XM. The 2024 Nucleic Acids Research database issue and the online molecular biology database collection. *Nucleic acids research*. 2024;52(D1):D1-D9.<https://doi.org/10.1093/nar/gkad1173>
- Fernández FJ, Querol-García J, Navas-Yuste S, *et al.* X-Ray Crystallography for Macromolecular Complexes. *Advances in experimental medicine and biology*. 2024;3234:125-140.<https://doi.org/10.1007/978-3-02140-6>
- Guo SB, Meng Y, Lin L, *et al.* Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation. *Molecular Cancer*. 2024;23(1):223.<https://doi.org/10.1186/s12943-024-02140-6>
- Depledge DP, Breuer J. Varicella-Zoster Virus-Genetics, Molecular Evolution and Recombination. *Current topics in microbiology and immunology*. 2023;438:1-23.https://doi.org/10.1007/82_2021_238
- Richards TA, Thomas A, Richards. *Current biology : CB*. 2023;33(7):R247-R248.<https://doi.org/10.1016/j.cub.2023.03.001>
- Yang LT, Chen LS. Stress Physiology and Molecular Biology of Fruit Crops. *International journal of molecular sciences*. 2024;25(2).<https://doi.org/10.3390/ijms25020706>
- Fatica M, D'Antonio A, Novelli L, *et al.* How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management. *Current rheumatology reports*. 2023;25(1):12-33.<https://doi.org/10.1007/s11926-022-022-33>
- Cui H, Tejada-Lapueta A, Brbić M, *et al.* Towards multimodal foundation models in molecular cell biology. *Nature*. 2025;640(8059):623-633.<https://doi.org/10.1038/s41586-025-08710-y>
- Calado AM, Seixas F, Pires MDA. Updating an Overview of Teratology. *Methods in molecular biology (Clifton, N.J.)*. 2024;2753:1-38.https://doi.org/10.1007/978-1-0716-3625-1_1
- Law AB, Schmitt NC. Laryngeal Anatomy, Molecular Biology, Cause, and Risk Factors for Laryngeal Cancer. *Otolaryngologic clinics of North America*. 2023;56(2):197-203.<https://doi.org/10.1016/j.otc.2022.12.001>
- Papa S, Ortolani C, Fernández P, *et al.* Flow Cytometry and Its Applications to Molecular Biology and Diagnosis 2.0. *International journal of molecular sciences*. 2023;24(22).<https://doi.org/10.3390/ijms242216215>
- Bhadauria V, Zhao W. The Molecular Genetics and Genomics of Plant-Pathogen Interactions. *International journal of molecular sciences*. 2024;25(7).<https://doi.org/10.3390/ijms25073970>
- Ning Y, Zhang Y, Kallen MA, *et al.* Cytogenetics and molecular genetics of myelodysplastic neoplasms. *Best practice & research. Clinical haematology*. 2023;36(4):101512.<https://doi.org/10.1016/j.beha.2023.101512>
- Bootsma S, Bijlsma MF, Vermeulen L. The molecular biology of peritoneal metastatic disease. *EMBO molecular medicine*. 2023;15(3):e15914.<https://doi.org/10.15252/emmm.202215914>
- Bridges AA, Guthrie L, Lehman M, *et al.* An exciting future for microbial molecular biology and physiology. *mBio*. 2025;16(8):e0069425.<https://doi.org/10.1128/mbio.00694-25>